GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Amikacin

Amikin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Professional source

Stanford - extended-interval amikacin starting schedule

Product / population
Adults; gram-negative extended-interval method
Renal measure
CrCl mL/min plus measured level

Dosing / renal protocol and limits

Adult initial amikacin: 15 mg/kg IV; CrCl >=60 every 24 hours, 40-59 every 36 hours, 30-39 every 48 hours. Not recommended below 30, HD or CRRT. Draw an 8-12-hour level, halve it for the Hartford graph, then individualize. Exclude pregnancy, major burns and significant ascites. This is not an NTM regimen.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/antimicrobial-dosing-protocols/SHC-Aminoglycoside-Dosing-Guide.pdf

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Professional guidance

Stanford - extended-interval amikacin starting schedule

Adults; gram-negative extended-interval method

Renal method: CrCl mL/min plus measured level
Retrieved: 2026-09-05

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The source opening dose and its subsequent 15 mg/kg/day discussion are not interchangeable. Both are retained as historical text; no automatic aminoglycoside dose calculation is generated from them.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/amikacin/

Usual Dosing (Adults)

Susceptible infection: 7.5 mg/kg IV q8 to 12h.

DOSAGE AND ADMINISTRATION

The patient's pretreatment body weight should be obtained for calculation of correct dosage. Amikacin Sulfate Injection, USP may be given intramuscularly or intravenously. The status of renal function should be estimated by measurement of the serum creatinine concentration or calculation of the endogenous creatinine clearance rate. The blood urea nitrogen (BUN) is much less reliable for this purpose. Reassessment of renal function should be made periodically during therapy.

Whenever possible, amikacin concentrations in serum should be measured to assure adequate but not excessive levels. It is desirable to measure both peak and trough serum concentrations intermittently during therapy. Peak concentrations (30-90 minutes after injection) above 35 micrograms per mL and trough concentrations (just prior to the next dose) above 10 micrograms per mL should be avoided. Dosage should be adjusted as indicated.

Intramuscular Administration for Patients with Normal Renal Function - The recommended dosage for adults, children and older infants with normal renal function is 15 mg/kg/day divided into 2 or 3 equal doses administered at equally-divided intervals, i.e., 7.5 mg/kg q.12h or 5 mg/kg q.8h. Treatment of patients in the heavier weight classes should not exceed 1.5 gram/day.

When amikacin is indicated in newborns, it is recommended that a loading dose of 10 mg/kg be administered initially to be followed with 7.5 mg/kg every 12 hours. The usual duration of treatment is 7 to 10 days. It is desirable to limit the duration of treatment to short term whenever feasible. The total daily dose by all routes of administration should not exceed 15 mg/kg/day. In difficult and complicated infections where treatment beyond 10 days is considered, the use of amikacin should be re-evaluated.

If continued, amikacin serum levels and renal, auditory, and vestibular functions should be monitored. At the recommended dosage level, uncomplicated infections due to amikacin-sensitive organisms should respond in 24 to 48 hours. If definite clinical response does not occur within 3 to 5 days, therapy should be stopped and the antibiotic susceptibility pattern of the invading organism should be rechecked.

Failure of the infection to respond may be due to resistance of the organism or to the presence of septic foci requiring surgical drainage. When amikacin is indicated in uncomplicated urinary tract infections, a dose of 250 mg twice daily may be used.

GRPH-amikacin-01 · Source section: Usual Dosing (Adults)Renal section finder

Dosage guidelines - adults and children with normal renal function

Weight lbWeight kg7.5 mg/kg q12h5 mg/kg q8h
9945337.5 mg225 mg
11050375 mg250 mg
12155412.5 mg275 mg
13260450 mg300 mg
14365487.5 mg325 mg
15470525 mg350 mg
16575562.5 mg375 mg
17680600 mg400 mg
18785637.5 mg425 mg
19890675 mg450 mg
20995712.5 mg475 mg
220100750 mg500 mg
GRPH-amikacin-02 · Source section: Dosage guidelines - adults and children with normal renal functionRenal section finder

Impaired renal function - original package-insert discussion

Intramuscular Administration for Patients with Impaired Renal Function - Whenever possible, serum amikacin concentrations should be monitored by appropriate assay procedures. Doses may be adjusted in patients with impaired renal function either by administering normal doses at prolonged intervals or by administering reduced doses at a fixed interval.

Both methods are based on the patient's creatinine clearance or serum creatinine values since these have been found to correlate with aminoglycoside half-lives in patients with diminished renal function. These dosage schedules must be used in conjunction with careful clinical and laboratory observations of the patient and should be modified as necessary. Neither method should be used when dialysis is being performed.

Normal Dosage at Prolonged Intervals - If the creatinine clearance rate is not available and the patient's condition is stable, a dosage interval in hours for the normal dose can be calculated by multiplying the patient's serum creatinine by 9, e.g., if the serum creatinine concentration is 2 mg/100 mL, the recommended single dose (7.5 mg/kg) should be administered every 18 hours.

Reduced Dosage at Fixed Time Intervals - When renal function is impaired and it is desirable to administer amikacin at a fixed time interval, dosage must be reduced. In these patients serum amikacin concentrations should be measured to assure accurate administration of amikacin and to avoid concentrations above 35 mcg/mL.

If serum assay determinations are not available and the patient's condition is stable, serum creatinine and creatinine clearance values are the most readily available indicators of the degree of renal impairment to use as a guide for dosage. First, initiate therapy by administering a normal dose, 7.5 mg/kg, as a loading dose. This loading dose is the same as the normally recommended dose which would be calculated for a patient with a normal renal function as described above.

To determine the size of maintenance doses administered every 12 hours, the loading dose should be reduced in proportion to the reduction in the patient's creatinine clearance rate.

Maintenance dose every 12 hours = (observed CC in mL/min / normal CC in mL/min) x calculated loading dose in mg.

(CC - creatinine clearance rate)

An alternate rough guide for determining reduced dosage at 12 hour intervals (for patients whose steady state serum creatinine values are known) is to divide the normally recommended dose by the patient's serum creatinine. The above dosage schedules are not intended to be rigid recommendations but are provided as guides to dosage when the measurement of amikacin serum levels is not feasible.

GRPH-amikacin-03 · Source section: Impaired renal function - original package-insert discussionRenal section finder

Renal Dosing

[CRCL >60 ml/min]: Give q8h (follow levels).

[40-60]: Give q12h (follow levels).

[20-40]: Give q24h (follow levels).

[10-20]: Give q48h (follow levels).

[<10 ml/min]: Give q48-72h (follow levels).

GRPH-amikacin-04 · Source section: Renal DosingRenal section finder

Hemodialysis

Hemodialysis: Administer dose post-dialysis or administer 2/3 normal dose as a supplemental dose post-dialysis and follow levels.

GRPH-amikacin-05 · Source section: HemodialysisRenal section finder
Separate professional-source layer

University and professional protocols

Professional

Stanford - extended-interval amikacin starting schedule

Open original reference

Open / share this exact local source

Stanford Health Care · Adults; gram-negative extended-interval method

Renal method: CrCl mL/min plus measured level
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult initial amikacin: 15 mg/kg IV; CrCl >=60 every 24 hours, 40-59 every 36 hours, 30-39 every 48 hours. Not recommended below 30, HD or CRRT. Draw an 8-12-hour level, halve it for the Hartford graph, then individualize. Exclude pregnancy, major burns and significant ascites. This is not an NTM regimen.

RDM30-106-amikacin-1 · Source locator: Stanford - extended-interval amikacin starting schedule; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/antimicrobial-dosing-protocols/SHC-Aminoglycoside-Dosing-Guide.pdf
Retrieved
2026-09-05
Renal-function method
CrCl mL/min plus measured level
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
798d3aa32af0846ba05e6834815f2cbb0d9e9b966aa3198ddaa1b3b31566be6e

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/amikacin/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
e9f444f71d10c98275d6f1dd7626d32f5891105e1d074e4a8c31a44e040016f0
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report